{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:21:39Z","timestamp":1784892099686,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002923","name":"CONICET","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008478","name":"Instituto Nacional del C\u00e1ncer","doi-asserted-by":"publisher","award":["INC III"],"award-info":[{"award-number":["INC III"]}],"id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008478","name":"Instituto Nacional del C\u00e1ncer","doi-asserted-by":"publisher","award":["IS001946"],"award-info":[{"award-number":["IS001946"]}],"id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017700","name":"Fundaci\u00f3n Sales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundaci\u00f3n C\u00e1ncer"},{"name":"Fundaci\u00f3n Pedro Mosoteguy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cutaneous melanoma is the skin cancer with the highest mutational burden and metastatic rate. Early genetic alterations and biomarkers of distant progression are a point of interest. In addition to germline-susceptibility loci, almost 30% of melanomas arise from precursor benign nevi lesions, providing a source for malignant transformation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Patient#009 developed a cutaneous melanoma over a nevus, followed by progression to regional and distant metastases in months, unresponsive to targeted therapy. To search for the genetic contribution to this rapid progression, a longitudinal analysis was performed through WES of germline, nevi, primary tumor, and a metastatic lymph node. Differential SNP\/INDEL and CNV gene alterations, with functional impact on key pathways and cancer hallmarks in each step of evolution, were discerned. Tumor-associated nevus was, for the first time, split into two sections, distant and adjacent to the primary tumor, to study its heterogeneity.<\/jats:p><jats:p>Shared SNP alterations, with stable allele fraction from germline to metastasis were detected, mainly affecting DNA repair genes and promoting genome instability. Early somatic alterations, shared by nevi and primary and metastatic tumors, included BRAF<jats:sup>V600E<\/jats:sup>and focal copy-loss of several genes, acquiring additional cancer hallmarks. Phylogenetic analyses revealed that these common somatic alterations would provide a \u201cbridge\u201d, allowing progression from a benign to a malignant state. Distant and adjacent nevi were rich in alterations, presenting differential SNP and CNV alterations. Upon tumor transformation, a marked increase in CNV over SNP alterations was determined. Both the number of SNP and CNV-affected genes, including known driver genes, increased throughout progression, although TMB levels remained lower than expected for melanoma. Typical alterations in BRAF<jats:sup>V600E<\/jats:sup>tumors related to intrinsic resistance to targeted therapy were found, including BRAF amplification and loss of PTEN, CDKN2A\/B, and TP53 surveillance genes. Finally, numerous metastatic alterations were detected, further promoting tumor progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12920-022-01426-2","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:03:49Z","timestamp":1672909429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Ana","family":"Mordoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Trivi\u00f1o Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibel","family":"Carri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Marcela","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-5845","authenticated-orcid":false,"given":"Mariana","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"1426_CR2","doi-asserted-by":"crossref","unstructured":"Guan J, Gupta R, Filipp F V. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Sci Rep. 2015;5.","DOI":"10.1038\/srep07857"},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380.","journal-title":"Nature"},{"key":"1426_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2018.03.033","volume":"173","author":"L Ding","year":"2018","unstructured":"Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell. 2018;173:305-320.e10.","journal-title":"Cell"},{"key":"1426_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/ng.3373","volume":"47","author":"MH Law","year":"2015","unstructured":"Law MH, Bishop DT, Lee J, Brossard M, Martin N, Moses E, et al. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet. 2015;47:987\u201395.","journal-title":"Nat Genet"},{"key":"1426_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jid.2018.02.012","volume":"138","author":"MS Stark","year":"2018","unstructured":"Stark MS, Tan JM, Tom L, Jagirdar K, Lambie D, Schaider H, et al. Whole-exome sequencing of acquired nevi identifies mechanisms for development and maintenance of benign neoplasms. J Invest Dermatol. 2018;138:1636\u201344.","journal-title":"J Invest Dermatol"},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/archderm.139.3.282","volume":"139","author":"H Tsao","year":"2003","unstructured":"Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003;139:282\u20138.","journal-title":"Arch Dermatol"},{"key":"1426_CR8","doi-asserted-by":"crossref","unstructured":"Lee KJ, Janda M, Stark MS, Sturm RA, Soyer HP. On Naevi and melanomas: two sides of the same coin? Front Med. 2021;1\u20138.","DOI":"10.3389\/fmed.2021.635316"},{"key":"1426_CR9","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373:1926\u201336.","journal-title":"N Engl J Med"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jid.2018.12.033","volume":"139","author":"AJ Colebatch","year":"2019","unstructured":"Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, et al. Molecular genomic profiling of melanocytic nevi. J Invest Dermatol. 2019;139:1762\u20138.","journal-title":"J Invest Dermatol"},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccell.2018.06.005","volume":"34","author":"AH Shain","year":"2018","unstructured":"Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, Prow T, et al. Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution. Cancer Cell. 2018;34:45-55.e4.","journal-title":"Cancer Cell"},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.jid.2020.02.021","volume":"140","author":"MS Stark","year":"2020","unstructured":"Stark MS, Denisova E, Kays TA, Heidenreich B, Rachakonda S, Requena C, et al. Mutation signatures in melanocytic nevi reveal characteristics of defective DNA repair. J Invest Dermatol. 2020;140:2093-2096.e2.","journal-title":"J Invest Dermatol"},{"key":"1426_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/his.13843","volume":"75","author":"JR Lozada","year":"2019","unstructured":"Lozada JR, Geyer FC, Selenica P, Brown D, Alemar B, Merghoub T, et al. Massively parallel sequencing analysis of benign melanocytic naevi. Histopathology. 2019;75:29\u201338.","journal-title":"Histopathology"},{"key":"1426_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fimmu.2015.00144","volume":"6","author":"M Aris","year":"2015","unstructured":"Aris M, Bravo AI, Barrio MM, Mordoh J. Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report. Front Immunol. 2015;6:144.","journal-title":"Front Immunol"},{"key":"1426_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fimmu.2017.00625","volume":"8","author":"J Mordoh","year":"2017","unstructured":"Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, et al. Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus bacillus calmette-guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patie. Front Immunol. 2017;8:625.","journal-title":"Front Immunol"},{"key":"1426_CR16","doi-asserted-by":"crossref","unstructured":"Zhang D, Huo D, Xie H, Wu L, Zhang J, Liu L, et al. CHG: a systematically integrated database of cancer hallmark genes. Front Genet. 2020;11.","DOI":"10.3389\/fgene.2020.00029"},{"key":"1426_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1479-5876-11-279","volume":"11","author":"J Rendleman","year":"2013","unstructured":"Rendleman J, Shang S, Dominianni C, Shields JF, Scanlon P, Adaniel C, et al. Melanoma risk loci as determinants of melanoma recurrence and survival. J Transl Med. 2013;11:279.","journal-title":"J Transl Med"},{"key":"1426_CR18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/jid.2012.498","volume":"133","author":"C Li","year":"2013","unstructured":"Li C, Wang M, Wang L-E, Amos CI, Zhu D, Lee JE, et al. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013;133:1813\u201321.","journal-title":"J Invest Dermatol"},{"key":"1426_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/pcmr.12212","volume":"27","author":"M Bhandaru","year":"2014","unstructured":"Bhandaru M, Martinka M, Li G, Rotte A. Loss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma. Pigment Cell Melanoma Res. 2014;27:366\u201375.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10389 adult cancers. Cell. 2018;173:355-370.e14.","journal-title":"Cell"},{"key":"1426_CR21","doi-asserted-by":"crossref","unstructured":"Aoude LG, Bonazzi VF, Brosda S, Patel K, Koufariotis LT, Oey H, et al. Pathogenic germline variants are associated with poor survival in stage III\/IV melanoma patients. Sci Rep. 2020;10.","DOI":"10.1038\/s41598-020-74956-3"},{"key":"1426_CR22","doi-asserted-by":"crossref","unstructured":"Li X, Mao W, Chen J, Goding CR, Cui R, Xu ZX, et al. The protective role of MC1R in chromosome stability and centromeric integrity in melanocytes. Cell Death Discov. 2021;7.","DOI":"10.1038\/s41420-021-00499-9"},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1087057116679592","volume":"22","author":"WJ Lee","year":"2017","unstructured":"Lee WJ, \u0160kalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, et al. Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discov Adv life Sci R D. 2017;22:298\u2013308.","journal-title":"SLAS Discov Adv life Sci R D"},{"key":"1426_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/tcmj.tcmj_158_20","volume":"34","author":"WW Sung","year":"2021","unstructured":"Sung WW, Chang CH. Nevi, dysplastic nevi, and melanoma: molecular and immune mechanisms involving the progression. Tzu chi Med J. 2021;34:1\u20137.","journal-title":"Tzu chi Med J"},{"key":"1426_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.det.2016.08.001","volume":"35","author":"JM Huang","year":"2017","unstructured":"Huang JM, Chikeka I, Hornyak TJ. Melanocytic nevi and the genetic and epigenetic control of oncogene-induced senescence. Dermatol Clin. 2017;35:85\u201393.","journal-title":"Dermatol Clin"},{"key":"1426_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/CMR.0000000000000671","volume":"30","author":"A Chavanet","year":"2020","unstructured":"Chavanet A, Hill KR, Jim\u00e9nez-Andrade Y, Choo MK, White K, Park JM. Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells. Melanoma Res. 2020;30:336\u201347.","journal-title":"Melanoma Res"},{"key":"1426_CR27","doi-asserted-by":"crossref","unstructured":"Catalanotti F, Cheng DT, Shoushtari AN, Johnson DB, Panageas KS, Momtaz P, et al. PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma. JCO Precis Oncol. 2017;1\u201315.","DOI":"10.1200\/PO.16.00054"},{"key":"1426_CR28","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1038\/onc.2016.526","volume":"36","author":"H Yang","year":"2017","unstructured":"Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, et al. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene. 2017;36:3842\u201351.","journal-title":"Oncogene"},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","volume":"8","author":"A Mehta","year":"2018","unstructured":"Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 2018;8:935\u201343.","journal-title":"Cancer Discov"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-022-01426-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T17:50:05Z","timestamp":1728669005000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-022-01426-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1186\/s12920-022-01426-2","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CASVAC-0401 study was carried out at the Instituto Alexander Fleming (Buenos Aires, Argentina) following the Declaration of Helsinki, and was approved by the Ethics Committee of that institution on 09\/29\/2014, resolution#354 (Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Instituto Alexander Fleming, Buenos Aires, Argentina). All enrolled patients signed informed consent for their participation in the clinical trial as well as for the publication of their data anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent from patient#009, along with testification from a next of kin, was obtained for the publication of her data anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}